Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...